Please login to the form below
small cell lung cancer
This page shows the latest small cell lung cancer news and features for those working in and with pharma, biotech and healthcare.
Novartis highlights emerging assets and late-stage pipeline at R&D day
Lu-PSMA-617, a radioligand therapy for prostate cancer which has phase 3 readouts due in the near future. ... Canakinumab (ACZ885), an IL-1 beta mAb for non-small cell lung cancer, which has trials being recruited in both the first- and second-line
Latest news
-
Seattle Genetics moves to dismiss ADC lawsuit with Daiichi Sankyo
a HER2-targeting drug for breast cancer that was licensed by AstraZeneca for $1.35bn upfront earlier this year. ... ADCs feature prominently in Daiichi’s oncology pipeline, with additional candidates in early stage testing for breast cancer,
-
AstraZeneca eyes early 2020 FDA verdict on Imfinzi in SCLC
for small cell lung cancer (SCLC), with a decision due in the first quarter of next year. ... SCLC is less common than non-small cell lung cancer (NSCLC) but is a particularly aggressive form, growing more quickly and spreading to other parts of the body
-
Merck’s Keytruda picks up third approval for NSCLC in China
of non-small cell lung cancer (NSCLC) in China in less than a year. . ... In less than one year, we have received three first-line approvals for Keytruda, in combination with chemotherapy or as monotherapy, in non-small cell lung cancer,” said Joseph
-
Roche’s Tecentriq/Avastin combo improves survival in liver cancer
the first phase 3 cancer immunotherapy study to show an improvement in overall survival in this setting. ... The Tecentriq/Avastin combination is already approved for non-squamous non-small cell lung cancer (NSCLC) without EGFR or ALK mutations, and as a
-
Takeda highlights 12 NMEs with $10bn-plus sales potential at R&D day
TAK-788 for non-small cell lung cancer:Phase 1/2 results with EGFR/HER2 inhibitor TAK-788 in non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations – ... a blood disorder that results in blood clots forming in small blood vessels
More from news
Approximately 3 fully matching, plus 601 partially matching documents found.
Latest Intelligence
-
Immuno-oncology in 2019: the rapid evolution continues
It sealed its dominance last year with a string of successful endpoint-hitting trials, most especially in non- small cell lung cancer (NSCLC). ... Keytruda extends its lead. Keytruda established itself as the new standard for first-line treatment of
-
Is China ready for a pharmaceutical gold rush?
Bristol-Myers Squibb’s (BMS)’s Opdivo (nivolumab) was approved for the treatment of non-small cell lung cancer (NSCLC) in June. ... For patients with previously chemo-treated advanced non-small cell lung cancer, Opdivo reduced the risk of death in
-
China: AstraZeneca’s new engine for growth and innovation
There is a good reason why Tagrisso was chosen for the fast track – the drug is for patients with epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung ... Its Imfinzi has secured the first-ever US and EU approval in
-
Chinese biotech’s global ambitions
has just achieved a landmark approval in China for its own ‘home-grown’ cancer medicine. ... Tislelizumab is in global phase III trials in a number of tumour types, including non-small cell lung cancer, hepatocellular carcinoma and oesophageal
-
Cancer immunotherapy: What's on the horizon?
had transformative results in some diseases such as melanoma, non-small cell lung cancer and bladder cancer – among others. ... Non-small cell lung cancer (NSCLC) is a prime example of the impact the new PD-(L) 1 drugs can have.
More from intelligence
Approximately 0 fully matching, plus 21 partially matching documents found.
Latest appointments
-
Merck appoints ex-Pfizer exec as global head of oncology
In this role, she will be responsible for defining the pharmaceutical company's integrated global oncology strategies and delivering therapeutic launches, including the commercial launch of Avelumab, a non-small cell ... lung cancer therapy, which is
-
BIND Therapeutics appoints Andrew Hirsch as permanent CEO
Its lead compound, BIND-014, is currently in phase II clinical trials for KRAS-mutant and squamous histology non-small cell lung cancer.
-
Charles Morris appointed chief development officer at ImmunoGen
Dr Morris, who joins from Allos Therapeutics, will oversee all aspects of product development for the US cancer-focused biotech. ... Its pipeline includes the investigational compounds IMGN901 - in phase II testing for the treatment of small-cell lung
-
Axelar appoints Carl Harald Janson as CEO
Takes control as company prepares to take novel cancer drug to proof-of-concept. ... The biotech is currently running a randomised phase II clinical trial with AXL1717 in non-small cell lung cancer (NSCLC) patients, while a first-in-man phase I/II
More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
The 2019 WHO essential medicine list: Narrowing the access gap to innovative cancer treatments
Lenalidomide. Revlimid. Celgene. Thalidomide. Thalomid. Celgene. Melphalan. Multiple brands. -. Erlotinib. Tarceva. Genentech. Front-line treatment of EGFR mutation positive advanced non-small cell lung cancer. ... Non-small cell lung cancer treatments,
-
Therapy Watch expands oncology and IBD portfolios
Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer ... PCa), Renal Cell Carcinoma (RCC) and
-
Therapy Watch expands its oncology portfolio
This month Therapy Watch Oncology will be expanding its portfolio with the addition of Squamous Cell Carcinoma of the Head and Neck (SCCHN). ... Therapy Watch SCCHN is part of a wider portfolio which covers Chronic Lymphocytic Leukaemia (CLL),
-
How pembrolizumab will change the management of advanced lung cancer
The results of the Phase III KEYNOTE-024 trial of pembrolizumab for non-small cell lung cancer (NSCLC) were presented by VJOncology Editorial Board Member Dr Martin Reck of LungenClinic Grosshansdorf. ... He explains that “this data will completely
-
A stumble, but not a fall – what’s next for Opdivo?
In this manner, it can crucially target several cancers, a property that was successfully exploited by BMS and resulted in securing FDA nods for treating non-small cell lung cancer (NSCLC) ... and renal cell carcinoma (kidney cancer).
More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.
Featured jobs
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
- Experienced / Senior Medical Writer - MedComms - Cardiff - Wales
-
Excellent Salary and Benefits on offer
- Account Manager / Senior Account Manager - Creative MedComms - C...
-
Excellent Remuneration
- Scientific Director - Medical Communications Agency - New York
-
Excellent Remuneration Package
- Scientific Director - Medical Education - Cheshire & London ...
-
Excellent Remuneration Package
- Senior Medical Writer – Leading Medical Communications Agency – ...
-
Highly Competitive Remuneration Package
-
Account Director, Medical Education
-
Salary TBC
- Graduate / Entry Level Opportunities – Medical Communications – ...
-
Highly Competitive Remuneration Package
-
Senior Medical Writer
-
Salary TBC
- Senior / Principal Medical Writer – Medical Education - UK &...
-
Excellent Salary and Benefits on offer
- Senior Medical Writer– Medical Education – Oxford - London
-
Excellent Remuneration Package
Subscribe to our email news alerts
- Moving annual total (MAT)
- Genital herpes vaccine candidate heads for human studies
- Seattle Genetics moves to dismiss ADC lawsuit with Daiichi Sankyo
- Creativity in storytelling: why pharma must invest more in creativity
- Pfizer takeover rumour ignites Amarin shares
- PMEA - Pharmaceutical Market Excellence Awards
- Five key trends in precision and personalised healthcare
- Biogen defends aducanumab filing plan amid scepticism
- UCB’s bimekizumab beats AbbVie’s Humira in phase 3 trial
- Novartis strengthens case for its combination asthma drug
- OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
- Sage slides off a MOUNTAIN as depression drug flunks trial
PMHub
SEVEN STONES
Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....
Latest intelligence
- Five key trends in precision and personalised healthcare
- Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
- OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
- Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...
- Language barriers: Obesity has become a loaded word
- ...
Quick links
Infographics
